Agios Pharmaceuticals, Inc. (AGIO)

Several events have impacted AGIO's stock price in the past six months. The FDA approved AQVESME in December 2025. Topline results from the Phase 3 RISE UP trial in Sickle Cell Disease were announced in November 2025. Agios reported Q4 and full-year 2025 financial results on February 12, 2026, including AQVESME FDA approval and PYRUKYND Q4 net revenue of $20.0M. Agios advanced mitapivat toward potential U.S. accelerated approval in sickle cell disease following a pre-sNDA meeting with the FDA on March 31, 2026. Agios reported Q1 2026 financial results on April 29, 2026, showing strong early demand for AQVESME in the U.S. with $18.8M in U.S. net revenue, leading to a 13.10% stock gain. Analyst sentiment has been mixed but cautious, with a "Hold" consensus and a target price of $41.56.

Information directly detailing demand seasonality for Agios Pharmaceuticals, Inc.'s products and services is not explicitly available. Demand for its approved therapies is likely relatively stable rather than highly seasonal, as these conditions require ongoing treatment. Quarterly revenue fluctuations have been noted, driven by ordering patterns, inventory dynamics, and gross-to-net adjustments, rather than inherent seasonality of demand for the underlying conditions. The company also noted expected variability in ex-U.S. quarterly revenues due to early market access dynamics and government procurement processes.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering therapies for rare diseases, particularly in classical hematology. Their key products include PYRUKYND (mitapivat), a PK activator approved for PK deficiency and in trials for thalassemia and sickle cell disease, and AQVESME (mitapivat), approved for anemia in adults with alpha- or beta-thalassemia. Other pipeline candidates include AG-946, Tebapivat, AG-181, and AG-236.

Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. PYRUKYND is marketed in the U.S., EU, and Great Britain for adult PK deficiency. AQVESME has launched in the U.S. Mitapivat has ex-U.S. net revenue, with thalassemia utilization in the GCC. The company is working on securing government procurement in Europe for PK deficiency.

Agios Pharmaceuticals has a reputation as a pioneering leader in cellular metabolism, focused on developing therapies for rare diseases, particularly hemolytic anemias. The company emphasizes its connections with patient communities, healthcare professionals, partners, and colleagues to discover and deliver therapies. The publication of the 2023 ESG report highlighted the company's progress on patient access, health equity, diversity, and flexibility. The FDA approval of AQVESME enhanced the company's reputation as an innovator in rare disease treatments. Advancing Mitapivat for Sickle Cell Disease further solidifies its position in addressing unmet medical needs.

Agios Pharmaceuticals, Inc. has significant institutional ownership, with 244 institutional owners holding 60,378,335 shares as of May 4, 2026, accounting for approximately 100.42% of the company's ownership, while individuals hold about 1.18%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Farallon Capital Management Llc. Major individual owners include Celgene European Investment Co LLC (10.01% ownership), Robert Nelsen (6.78% ownership), and Arch Venture Fund VII LP (5.27% ownership). Insider trading activity in the past three months has shown net selling.